spacer
home > ict > autumn 2009 > cold chain on the global stage
PUBLICATIONS
International Clinical Trials

Cold Chain on the Global Stage

 

Conducting clinical trials accounts for nearly one third of drug development costs, according to a recent report from Frost & Sullivan (1). In fact, the cost per patient of running Phase III clinical studies of new pharmaceuticals now tends to exceed $26,000 (2). One of the major causes of rising R&D costs is that 80 per cent of clinical trials fail to recruit patients on time (3). The migration of clinical trials into emerging markets offers a possible resolution to this issue; however, as with many aspects of drug development, this approach does not come without obstacles. This article will outline logistical issues involved in conducting clinical trials in emerging markets, and highlight measures that pharma and biotech companies can implement to ensure compliant transportation of temperature-sensitive clinical trial samples and supplies on time.

ADVANTAGES OF EMERGING MARKETS

Throughout traditional patient recruiting grounds, such as North America and western Europe, sponsors have historically competed for a limited pool of investigators and patients. Emerging clinical trial regions such as South America, eastern Europe and Asia offer access to large patient populations, the majority of which are treatment-naive. In countries within eastern Europe, sponsors have reported that recruitment rates are five to 10 times higher than in western Europe and the US (4). Furthermore, countries such as Brazil, Mexico and Argentina provide substantial advantages to sponsors conducting clinical trials there. As North and South America share the same Western hemisphere, they also share many of the same prevalent diseases. However, seasonal diseases occur six months out of phase between North America and Europe, giving researchers the ability to conduct year-round seasonal trials, which can significantly reduce development times for seasonal medications (5).

Although these regions provide access to large, treatmentnaive populations, emerging markets present regulatory and logistical challenges for companies conducting clinical trials there. Accordingly, it is paramount that pharmaceutical companies fully understand the complexities of shipping clinical trial samples and supplies to emerging countries. This will ensure any potential benefits are not compromised due to inadequate knowledge and preparation.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As Global Head of Logistics and Facilities, Jeff Clark oversees BioStorage Technologies’ day-to-day cold chain logistics for the US and Europe. He is responsible for ensuring the integrity of clients’ biological materials throughout all phases of shipping, handling, tracking and storage. In this role, Jeff develops and manages all logistics and customer service processes, defines requirements for the company’s proprietary sample management system, and negotiates global transportation and logistics partnerships. Jeff holds a diploma from the International Air Transport Association (IATA) and International Federation of Freight Forwarders Association (FIATA). He also earned certifications in international rates and tariffs, advanced cargo agent 803-53/01 and IATA hazmat training, and is a member of the American Chemical Council.
spacer
Jeff Clark
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement